Zhilan Health Collaborates on Zhangjiang Digital Biopharma (Digital Therapeutics) Platform to Accelerate Industry-Academia Translation

On the afternoon of June 28, the Seminar on the New Digital Ecosystem for Biopharmaceuticals and the Launch Ceremony of the Zhangjiang Digital Biopharmaceutical (Digital Therapeutics) Industry-Research Translation Service Platform were successfully held in Zhangjiang. The event was hosted by Shanghai Zhangjiang Group and organized by SLANHEALTH, with support from Shanghai International Medical Park Group Co., Ltd., Siemens Healthineers Shanghai Innovation Center, Tigermed, Dian Diagnostics, Taifu Capital, Qiming Venture Partners, Anheng Information, Pacific Health Insurance, Zhangke Herun, JESA Capital, and other organizations (listed in no particular order).

Yuan Tao, Party Secretary and Chairman of Shanghai Zhangjiang (Group) Co., Ltd.; Wang Kairong, Deputy General Manager of Shanghai Zhangjiang (Group) Co., Ltd.; Wu Hao, Co-President of Tigermed; He Wei, Head of Siemens Healthineers Shanghai Innovation Center; Hu Xubo, Managing Partner of Qiming Venture Partners; Xia Duo, General Manager of Shanghai International Medical Park Group Co., Ltd.; Gao Yunlong, General Manager of SLANHEALTH; Jiang Tang, Senior Vice President of Dian Diagnostics and Founder of Xiao Fei Jian; Yan Xinxing, Senior Vice President of DBAPPSecurity and General Manager of its Shanghai Headquarters; Zhou Yachao, Chief Scientist at DBAPPSecurity’s Shanghai Headquarters; Shang Jiaoyan, General Manager of Pacific Health Insurance Co., Ltd.; Ding Gang, Director of the Oncology Center at Shanghai International Medical Center; Wang Jinghong, Founder of JESA Capital; and Du Hao, Head of Wexin Kang at Air Liquide China, were among the attendees.

Yuan Tao, Secretary of the Party Committee and Chairman of Shanghai Zhangjiang (Group) Co., Ltd., stated in his address that digital therapeutics have introduced new variables and opportunities to the biopharmaceutical industry. By establishing the Zhangjiang Digital Biopharma (Digital Therapeutics) Industry-Research Translation Service Platform, the company aims to better promote the transformation and upgrading of Zhangjiang’s digital biopharma sector and empower its biopharmaceutical enterprises.

Yuan Tao, Party Secretary and Chairman of Shanghai Zhangjiang (Group) Co., Ltd.

In his address, Wu Hao, Co-President of Tigermed, noted that the biopharmaceutical industry, as a key strategic emerging sector, is accelerating its embrace of digitalization. As a leading CRO in the industry, Tigermed is expediting the digital transformation across its entire group and operations, positioning digitalization as one of our core corporate development strategies.

Wu Hao, Co-President of Tigermed

He Wei, Head of the Siemens Healthineers Shanghai Innovation Center, stated in his address that Siemens Healthineers is working closely with service platforms to address key challenges in integrating healthcare scenarios with digital platforms. By leveraging technological, industrial, and ecosystem empowerment, the company supports the implementation and application of digital therapeutics.

He Wei, Head of Siemens Healthineers Shanghai Innovation Center

At the conference, Shanghai Zhangjiang Group and Hangzhou SLANHEALTH jointly initiated the establishment of the Zhangjiang Digital Biopharma (Digital Therapeutics) Industry-Research Translation Service Platform. Xia Duo, General Manager of Shanghai International Medical Park Group Co., Ltd., and Gao Yunlong, General Manager of SLANHEALTH, jointly unveiled the platform. Yuan Tao, Party Secretary and Chairman of Shanghai Zhangjiang (Group) Co., Ltd., Wu Hao, Co-President of Tigermed, and Hu Xubo, Managing Partner of Qiming Venture Partners, witnessed the launch of the platform.

The Zhangjiang Digital Biopharma (Digital Therapeutics) R&D and Commercialization Service Platform focuses on addressing core technical challenges in the research, development, commercialization, and application of digital products within the biopharmaceutical sector. By enhancing supporting services for the digital therapeutics industry through a collaborative innovation ecosystem integrating industrial parks, healthcare institutions, academia, research entities, capital, and end-users, the platform incubates digital therapeutics products, facilitates the translation and industrialization of clinical achievements in digital biopharma, and enriches the product pipeline of Zhangjiang’s biopharmaceutical industry.

The service platform will establish a national-level new engine for digital therapeutics, building a platform capability support system comprising disease coverage, industry linkages, empowerment dimensions, resource elements, and ecosystem synergy. Currently, the platform possesses one-stop capabilities for the research, development, and translation of digital biopharmaceuticals (digital therapeutics), high-level clinical research capabilities, and end-to-end R&D capabilities. By deeply integrating in vitro diagnostics (IVD) and intelligent wearable devices, it provides comprehensive support and services for the product development, data management, clinical trials, regulatory approval, and market launch of digital therapeutics.

The Digital Biopharma (Digital Therapeutics) Innovation Ecosystem Alliance was jointly initiated by Shanghai Zhangjiang Group, Shanghai International Medical Park Group Co., Ltd., SLANHEALTH, Anheng Information, Dian Diagnostics, and Pacific Health Insurance. The Alliance will integrate ecosystem stakeholders—including medical institutions, research institutes, digital therapeutics companies, biopharmaceutical enterprises, insurance providers, and investment and financing institutions—to comprehensively cover the entire chain of industry, academia, research, and application. It aims to precisely coordinate and align with the needs of the digital therapeutics ecosystem, fostering complementary capabilities, positive interaction, resource sharing, and integrated development.

From left to right: Zhou Yachao, Chief Scientist at Anheng Information’s Shanghai Headquarters; Jiang Dang, Senior Vice President of Dian Diagnostics and Founder of Xiaofei Jian; Gao Yunlong, General Manager of SLANHEALTH; Wang Kairong, Deputy General Manager of Shanghai Zhangjiang (Group) Co., Ltd.; Shang Jiaoyan, General Manager of Pacific Health Insurance Co., Ltd.; and Du Hao, Head of Vivisol China at Air Liquide Group.

BirthThe Alliance will continue to consolidate core forces in the digital therapeutics industry, promote deep integration of industry, academia, and research, facilitate cross-sector exchange and cooperation, collaborate with ecosystem partners to build a robust system for the aggregation and operation of digital resources, enhance the driving effect across the industrial chain, and support industrial upgrading and innovation.

China has designated health and medical big data as a critical foundational strategic resource. The vast volume of healthcare big data will be extensively applied in areas such as clinical decision support, drug research and development, remote patient data analysis, and public health, yielding substantial economic and social value. This trend poses greater challenges and higher requirements for the digital biopharmaceutical industry, represented by digital therapeutics, particularly in ensuring data information security and unlocking data value.

As China’s leading CDMO and full-process service platform for digital therapeutics, SLANHEALTH has partnered with DBAppSecurity, a company dedicated to safeguarding data security, to jointly build a data security platform for digital biopharmaceuticals (digital therapeutics). Yan Xinxing, Senior Vice President of DBAppSecurity and General Manager of its Shanghai Headquarters, and Ma Wenyue, Senior Partner at SLANHEALTH, attended the signing ceremony.

The data security platform will focus on empowering the biopharmaceutical sector with digital AI security, explore standards for data security in digital biomedicine, prevent and mitigate medical data security risks, and fully leverage the value of data. This initiative aims to support business growth in the digital biopharmaceutical industry, exemplified by Zhangjiang, and jointly build a secure future for digital healthcare.

As an innovative digital therapeutics CDMO and full-process service provider in China, SLANHEALTH is based in Zhangjiang, Shanghai. It has initiated the Zhangjiang Digital Biopharma (Digital Therapeutics) Industry-Research Translation Service Platform, the Innovation Ecosystem Alliance, and the Data Security Platform. As an industry leader, it joins hands with partners to forge ahead in the field of digital therapeutics. Gao Yunlong, General Manager of SLANHEALTH, stated that leveraging its capabilities in innovative industry-research translation and platform services, SLANHEALTH bridges digital technologies with medical research achievements, integrates the needs of hospitals, patients, pharmaceutical companies, and medical device manufacturers, and leads the translation of scientific research outcomes through cutting-edge technologies such as digital therapeutics. The company is committed to working collaboratively with partners to promote the high-quality development of the digital therapeutics industry in Zhangjiang.

Gao Yunlong, General Manager of SLANHEALTH

As a leading enterprise in cybersecurity, a practitioner of the market-oriented development of data factors across China, and a co-builder of the data security platform for digital biopharmaceuticals (digital therapeutics), Anheng InformationA comprehensive, end-to-end data security solution will be implemented through a data security platform to strengthen data security management and control in the digital biopharmaceutical sector. Dr. Zhou Yachao, Chief Scientist at Anheng Information’s Shanghai headquarters, highlighted the value of the data security platform, which enables more precise control through data classification and grading. The platform establishes a robust data security defense line for partner enterprises in the healthcare sector, maximizing the value of data assets while ensuring regulatory compliance, thereby facilitating the application of digital therapeutics across diverse scenarios. In the future, the company will also actively participate in the development of data security standards for digital therapeutics.

Zhou Yachao, Chief Scientist at Anheng Information’s Shanghai Headquarters

With third-party diagnostic services as its core business, Dian Diagnostics is committed to providing integrated medical diagnostic solutions. Jiang Tang, Senior Vice President of Dian Diagnostics and founder of Xiao Fei Jian, stated from the perspective of industrial capital that digital therapeutics will give rise to multi-dimensional commercial scenarios and innovative applications in the future. By combining in vitro diagnostics with wearable devices, more digital therapeutic products will be developed and applied in scenarios such as medical care, chronic disease management, and health management, thereby reducing healthcare costs and improving medical outcomes and quality. As a significant model, digital therapeutics are driving the reform and upgrading of disease diagnosis and treatment methods.

Jiang Dang, Senior Vice President of Dian Diagnostics and Founder of Xiaofeijian

Furthermore, during the roundtable discussion, distinguished guests including Dr. Ding Gang, Director of the Oncology Center at Shanghai International Medical Center; Mr. Shang Jiaoyan, General Manager of Pacific Health Insurance Co., Ltd.; and Ms. Wang Jinghong, Founder of JESA Capital, participated in discussions on “Digital Strategies in Biopharmaceuticals,” exploring the boundless possibilities for the future development of digital therapeutics.

Ding Gang, Director of the Oncology Center at Shanghai International Medical Center, pointed out that cancer is increasingly being managed as a chronic disease. After completing in-hospital treatment, patients still require medical services in the home care setting; however, physicians typically lack sufficient time and energy to provide effective follow-up management. Digital therapeutics, as a digital tool, can facilitate better disease management and follow-up for patients in home settings, strengthen doctor-patient communication, and enhance the overall patient healthcare experience.

Shang Jiaoyan, General Manager of Pacific Health Insurance Co., Ltd., noted that while insurance products cover medical liabilities, the transformation on the supply side brought by digital therapeutics has posed many new challenges for insurers’ product innovation, while also creating new opportunities. On one hand, incorporating digital therapeutics into policy coverage expands the health services offered within current health insurance products, delivering a superior insurance experience to customers. On the other hand, the emergence of digital therapeutics enables early disease screening, diagnosis, precision treatment, and rehabilitation, thereby facilitating refined innovative practices in insurance for individuals with pre-existing conditions.

In China’s capital markets, digital therapeutics (DTx) is regarded as a high-potential sector, with strong investor confidence. Wang Jinghong, founder of JESA Capital, believes that DTx companies should build core competitiveness across three dimensions: technological barriers, data barriers, and service and brand barriers. Among these, the most critical capabilities are data acquisition and model development. Platform-oriented enterprises like SLANHEALTH must also take responsibility for proactively engaging with regulatory frameworks—for example, by contributing to the improvement and development of the DTx regulatory system, thereby providing reverse empowerment to the industry.